Thermo Fisher Scientific (TMO) Total Non-Current Liabilities (2009 - 2026)

Thermo Fisher Scientific has disclosed Total Non-Current Liabilities across 18 years of filings, most recently posting $56.9 billion for Q1 2026.

• Quarterly Total Non-Current Liabilities rose 24.53% year-over-year to $56.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.9 billion (up 24.53% YoY) and the FY2025 annual result came in at $52.7 billion, up 20.29% from the prior year.
• Total Non-Current Liabilities advanced to $56.9 billion in Q1 2026, from $52.7 billion in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $56.9 billion in Q1 2026 and troughed at $42.5 billion in Q4 2022.
• A 5-year average of $47.4 billion and a median of $47.0 billion in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities soared 71.08% — and 2024, when it retreated 7.56%.
• Tracing TMO's Total Non-Current Liabilities over 5 years: stood at $48.9 billion in 2022, then fell by 3.12% to $47.4 billion in 2023, then fell by 7.56% to $43.8 billion in 2024, then increased by 20.29% to $52.7 billion in 2025, then climbed by 8.09% to $56.9 billion in 2026.
• Business Quant data shows TMO's Total Non-Current Liabilities at $56.9 billion in Q1 2026, $52.7 billion in Q4 2025, and $47.7 billion in Q3 2025.